Novartis Uk Ltd.
FRIMLEY, England, April 13, 2010 - Developed for UK consumer and medical journalists
Not intended for media in Republic of Ireland
New Data Presented at the AAN Show That Treatment With Fingolimod:
- Improves Self-Reported Ability to Perform Daily Activities for People
With Multiple Sclerosis (MS)
- Reduces Severity of Relapses, as Compared to Interferon Beta -1a, With
Significantly Less Need for Steroid Intervention and Hospitalisation
- Benefits Patients Switched From Interferon Beta -1a to Fingolimod, With
Significantly Reduced Relapse Rates and Improved Brain Lesion Measures
- Reduces Relapses by 62% in Newly Treated Patients
The recent publication of two pivotal studies (FREEDOMS and
TRANSFORMS) in the New England Journal of Medicine (NEJM) confirmed that
daily multiple sclerosis pill, fingolimod, was twice as effective as a
commonly used injection (interferon Beta -1a) and placebo for the treatment
of relapsing-remitting multiple sclerosis (RRMS) - the most common form of
the disease.(1,2,3) New data presented this week at the 62nd annual meeting
of the American Academy of Neurology (AAN) adds to the growing body of
evidence to support fingolimod, showing additional benefits for patients.
